6.99
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kintara Therapeutics Inc | KTRA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 6.99 | 04:00:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.99 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.5022 - 42.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 6.99 | USD |
Period:
Draw Mode:
Kintara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 11.30M | 1.62M | 1.61M | $ - | $ - | -27.50 | -0.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 4.48M | 3.50% |
Kintara Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KTRA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.70 | 7.65 | 5.91 | 6.44 | 27,970 | 0.29 | 4.33% |
| 1 Month | 8.01 | 8.4777 | 5.59 | 6.86 | 31,020 | -1.02 | -12.73% |
| 3 Months | 4.45 | 15.4999 | 3.5022 | 5.93 | 564,265 | 2.54 | 57.08% |
| 6 Months | 18.35 | 20.00 | 3.5022 | 7.83 | 2,002,847 | -11.36 | -61.91% |
| 1 Year | 21.58 | 42.00 | 3.5022 | 10.92 | 2,183,554 | -14.59 | -67.61% |
| 3 Years | 60.50 | 167.50 | 3.5022 | 35.04 | 1,470,076 | -53.51 | -88.45% |
| 5 Years | 60.50 | 167.50 | 3.5022 | 35.04 | 1,470,076 | -53.51 | -88.45% |
Kintara Therapeutics Description
| Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America. |
